Declaration of interests
Cancer, Endocyte/Novartis, W81XWH2010136, Prostate Cancer, RA, Nutcracker
ONCOLOGY, PROSTATE CANCER, CANCER
RA reports research grants to their institution from the Prostate Cancer Foundation, National Cancer Institute, Merck, Novartis, Janssen Pharmaceuticals; personal fees from Pfizer, Jubliant Therapeutics, Bayer, Exelixis, Targeted Oncology, Lumanity, EcoR1, Bioexcel, and Amgen; and is a member of the data safety monitoring board for the Prostate Cancer Clinical Trials Consortium/DORA phase 3 trial. TAH reports grants to their institution from Clovis Oncology, Philips, GE Healthcare, Lantheus, the Prostate Cancer Foundation, and the National Cancer Institute (R01CA235741 and R01CA212148); personal fees from Ipsen, Bayer, and BlueEarth Diagnostics; and personal fees from and has an equity interest in RayzeBio and Curium. FYF reports consulting fees from Novartis, Janssen, Bayer, Bristol-Myers Squibb, Sanofi, Roivant, Myovant, Astellas, and Point; serves as an advisor to Artera; and has received research grants from the Prostate Cancer Foundation and the National Cancer Institute (R01CA235741). LF reports research grants from Abbvie, Bavarian Nordic, Bristol-Myers Squibb, Dendreon, Janssen, Merck, and Roche/Genentech; and ownership interests in Actym, Atreca, Bioatla, Bolt, Keyhole, Immunogenesis, Nutcracker, RAPT, Scribe, and Senti, unrelated to this study. JC has received research grants from the Prostate Cancer Foundation, the National Cancer Institute (K08CA273514) and Department of Defense Prostate Cancer Program (W81XWH2010136); and personal fees from Exai Bio, outside the scope of this work. IdK has received research grants to the institution from the Prostate Cancer Foundation and ASCO Conquer Cancer Foundation; and consulting fees from Janssen Pharmaceuticals. VSK reports research grants to their institution from the Prostate Cancer Foundation, Eli Lilly, Merck, Seagen, Endocyte/Novartis, Nektar, Clovis, Janssen, and Taiho. RB reports research grants from the National Cancer Institute (1K08CA226348), Department of Defense, American Cancer Society, Prostate Cancer Foundation, and the UCSF Benioff Institute for Prostate Cancer Research; and received personal fees from Janssen. DYO has received research grants from Prostate Cancer Foundation, National Cancer Institute, Merck, PACT Pharma, the Parker Institute for Cancer Immunotherapy, Poseida Therapeutics, TCR